{"id":1110,"date":"2026-04-17T14:51:43","date_gmt":"2026-04-17T14:51:43","guid":{"rendered":"https:\/\/medycyna-gorska.pl\/?p=1110"},"modified":"2026-04-17T17:07:15","modified_gmt":"2026-04-17T17:07:15","slug":"acetazolamide-mechanism-of-action","status":"publish","type":"post","link":"https:\/\/medycyna-gorska.pl\/en\/acetazolamide-mechanism-of-action\/","title":{"rendered":"Acetazolamide \u2014 Mechanism of Action and Carbonic Anhydrase"},"content":{"rendered":"\n<p><strong>Acetazolamide<\/strong> (trade names <strong>Diamox<\/strong> internationally, <strong>Diuramid<\/strong> in Poland) is the most frequently used drug for prevention and treatment of acute mountain sickness. Its mechanism of action extends far beyond &#8220;AMS treatment&#8221; \u2014 it has been used for over 70 years in glaucoma, epilepsy, metabolic alkalosis, and idiopathic intracranial hypertension. Understanding exactly how it works allows sensible dosing, predicting side effects, and separating myths from facts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Acetazolamide in a nutshell \u2014 three-sentence mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Carbonic anhydrase inhibitor<\/strong> \u2014 blocks the enzyme that metabolizes carbon dioxide in kidneys, eyes, brain, and erythrocytes.<\/li>\n<li>In kidneys: increased excretion of bicarbonate and water \u2192 <strong>metabolic acidosis<\/strong>.<\/li>\n<li>Acidosis stimulates the respiratory center in the brainstem \u2192 deeper breathing \u2192 <strong>higher oxygen saturation and faster acclimatization<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What is carbonic anhydrase?<\/h2>\n\n\n\n<p><strong>Carbonic anhydrase (CA)<\/strong> is a family of enzymes catalyzing the reversible reaction:<\/p>\n\n\n\n<p style=\"text-align:center\"><strong>CO\u2082 + H\u2082O \u21cc H\u2082CO\u2083 \u21cc H\u207a + HCO\u2083\u207b<\/strong><\/p>\n\n\n\n<p>Without this enzyme the reaction would proceed too slowly for efficient CO\u2082 transport from tissues to lungs. Humans express at least 15 CA isoforms. The most relevant for acetazolamide pharmacology:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CA II<\/strong> \u2014 in erythrocytes, renal tubules, ciliary body epithelium of the eye, central nervous system<\/li>\n<li><strong>CA IV<\/strong> \u2014 in renal tubules (brush border) and pulmonary vessels<\/li>\n<li><strong>CA XII<\/strong> \u2014 in ciliary body epithelium<\/li>\n<\/ul>\n\n\n\n<p>Acetazolamide inhibits primarily CA II and CA IV \u2014 and this selectivity explains most of its clinical effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Mechanism in mountain medicine \u2014 step by step<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Carbonic anhydrase blockade in kidneys<\/h3>\n\n\n\n<p>In the proximal and distal renal tubules carbonic anhydrase drives reabsorption of bicarbonate (HCO\u2083\u207b) \u2014 approximately 85% of the filtrate. Acetazolamide blocks this process. Effect: <strong>increased urinary loss of bicarbonate<\/strong>, accompanied by sodium and water (hence the diuretic effect).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Metabolic acidosis \u2014 controlled and desirable<\/h3>\n\n\n\n<p>Loss of HCO\u2083\u207b in urine shifts blood toward acidity (pH drops from 7.40 to 7.32\u20137.36). This is mild metabolic acidosis, clinically insignificant in healthy individuals \u2014 but <strong>sufficient to stimulate chemoreceptors<\/strong> in the medulla oblongata that monitor pH and CO\u2082 pressure.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><picture><source type=\"image\/webp\" srcset=\"https:\/\/medycyna-gorska.pl\/wp-content\/uploads\/2023\/08\/IMG_20220413_124012.webp\"><img decoding=\"async\" src=\"https:\/\/medycyna-gorska.pl\/wp-content\/uploads\/2023\/08\/IMG_20220413_124012.jpg\" alt=\"Expedition medical kit with altitude sickness drugs \u2014 acetazolamide, dexamethasone, nifedipine\" class=\"wp-image-759\"\/><\/picture><figcaption class=\"wp-element-caption\">Expedition medical kit with mountain medicine drugs. Acetazolamide (Diuramid) is only one element \u2014 not a single tablet but a plan tailored to the specific expedition.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">3. Compensatory hyperventilation<\/h3>\n\n\n\n<p>Chemoreceptors detect lower pH and signal the respiratory center: <em>breathe faster and deeper to exhale more CO\u2082 and restore acid-base balance<\/em>. Results:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Minute ventilation rises by 10\u201330%<\/li>\n<li>More oxygen reaches alveoli \u2192 higher blood saturation<\/li>\n<li>Higher saturation = less tissue hypoxia = reduced AMS risk<\/li>\n<\/ul>\n\n\n\n<p>At altitude the body physiologically hyperventilates but often &#8220;not enough&#8221;. Acetazolamide is in practice a <strong>pharmacological forcing of this compensation<\/strong> \u2014 the body reacts as if already acclimatized, though physiologically still adjusting. Hence the shortened adaptation time.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Additional beneficial effects<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced respiratory alkalosis<\/strong> \u2014 physiological altitude hyperventilation causes respiratory alkalosis that paradoxically limits further ventilation increase. Acetazolamide &#8220;releases this brake&#8221;.<\/li>\n<li><strong>Improved sleep breathing stability<\/strong> \u2014 at altitude Cheyne-Stokes breathing (alternating apneas and hyperventilation) fragments sleep and worsens nocturnal hypoxia. Acetazolamide reduces frequency and depth of these episodes.<\/li>\n<li><strong>Moderate diuretic effect<\/strong> \u2014 useful in mild peripheral edema, but at altitude watch hydration carefully.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Other indications \u2014 beyond mountain medicine<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Glaucoma<\/strong> \u2014 reduces aqueous humor production by ciliary body epithelium (CA II and XII), lowering intraocular pressure. Dose 250 mg 2\u20134\u00d7\/day.<\/li>\n<li><strong>Epilepsy<\/strong> \u2014 stabilizes neuronal membranes (CA blockade in CNS limits depolarization). Used in <em>petit mal<\/em> in children and <em>grand mal<\/em> in adults. Shows efficacy in catamenial epilepsy (cyclic regimen).<\/li>\n<li><strong>Metabolic alkalosis<\/strong> \u2014 e.g. after prolonged mechanical ventilation or loop diuretic use.<\/li>\n<li><strong>Idiopathic intracranial hypertension<\/strong> (pseudotumor cerebri) \u2014 reduces cerebrospinal fluid production.<\/li>\n<li><strong>Drug- or cardiac-induced edema<\/strong> (rare indication today, replaced by newer diuretics).<\/li>\n<\/ul>\n\n\n\n<p>AMS use is <strong>off-label<\/strong> in many countries, but <strong>Wilderness Medical Society Guidelines 2019<\/strong> and European UIAA MedCom and ICAR MedCom consensuses clearly recommend acetazolamide in AMS prophylaxis and early treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pharmacokinetics \u2014 practical essentials<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Absorption:<\/strong> rapid, complete; plasma peak after ~2 h<\/li>\n<li><strong>Distribution:<\/strong> good blood-brain and placental barrier penetration<\/li>\n<li><strong>Protein binding:<\/strong> ~90% \u2014 relevant for interactions with albumin-bound drugs<\/li>\n<li><strong>Metabolism:<\/strong> virtually none \u2014 not metabolized in liver, excreted mostly unchanged<\/li>\n<li><strong>Excretion:<\/strong> 70\u2013100% in urine within 24 h<\/li>\n<li><strong>Half-life:<\/strong> 4\u20138 h<\/li>\n<li><strong>Steady state:<\/strong> reached after ~48 h of regular dosing \u2014 hence the recommendation to start 24 h before planned altitude exposure<\/li>\n<\/ul>\n\n\n\n<p>The drug is safe in hepatic insufficiency (no hepatic metabolism) but requires caution in severe renal insufficiency (GFR &lt;30 mL\/min) \u2014 accumulation and amplified side effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Side effects \u2014 mechanism and minimization<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Paresthesias (tingling in fingers and around the mouth)<\/h3>\n\n\n\n<p>Occur in 60\u201390% of patients taking acetazolamide. Mechanism: mild metabolic acidosis + decreased CO\u2082 alter calcium and potassium ion exchange in sensory neuron membranes. Paresthesias are usually mild, symptoms intensify during exertion (hyperventilation). Not dangerous \u2014 they indicate the drug is working.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Diuresis and frequent urination<\/h3>\n\n\n\n<p>Direct effect of blocked HCO\u2083\u207b reabsorption in kidneys. <strong>Increase fluid intake by 1\u20132 L\/day<\/strong> during acetazolamide use. Take the evening dose early (6\u20137 PM), not right before sleep \u2014 avoid nocturnal toilet trips in cold conditions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Taste disturbances<\/h3>\n\n\n\n<p>Classic harmless side effect: carbonated drinks taste &#8220;metallic&#8221; or &#8220;stale&#8221;. Mechanism: acetazolamide blocks CA in taste bud cells responsible for sour taste and &#8220;fizziness&#8221; perception. Cola, beer, mineral water have a very specific taste on acetazolamide \u2014 nothing to do but wait for drug withdrawal.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Rare serious side effects<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sulfonamide-type allergic reactions<\/strong> \u2014 acetazolamide contains a sulfonamide group. Cross-reactivity risk in patients allergic to sulfonamides (e.g. trimethoprim\/sulfamethoxazole, sulfasalazine): rash, angioedema, rarely Stevens-Johnson syndrome. Contraindication.<\/li>\n<li><strong>Agranulocytosis<\/strong> \u2014 granulocyte count &lt;0.5 G\/L. Frequency &lt;0.01%. Symptoms: high fever, sore throat, severe general condition.<\/li>\n<li><strong>Kidney stones<\/strong> \u2014 with long-term use (months). Minor issue in mountain medicine (1\u20133 weeks), relevant in glaucoma or IIH treatment.<\/li>\n<li><strong>Hypokalemia<\/strong> \u2014 at doses above 750 mg\/day and use &gt;2 weeks consider potassium supplementation (20 mmol\/day).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Contraindications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sulfonamide allergy<\/strong> \u2014 absolute<\/li>\n<li><strong>Severe renal insufficiency<\/strong> (GFR &lt;30 mL\/min) \u2014 absolute<\/li>\n<li><strong>Severe hepatic insufficiency with cirrhosis<\/strong> \u2014 acetazolamide worsens tubular alkalosis, risk of hepatic encephalopathy<\/li>\n<li><strong>Uncorrected hypokalemia<\/strong><\/li>\n<li><strong>Addison&#8217;s disease<\/strong><\/li>\n<li><strong>Hyperchloremic acidosis<\/strong><\/li>\n<li><strong>First trimester of pregnancy<\/strong> \u2014 relative; teratogenicity data mixed<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Drug interactions<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aspirin (high doses)<\/strong> \u2014 acetazolamide metabolic acidosis + salicylism = risk of severe acidosis and salicylate toxicity. Avoid combination.<\/li>\n<li><strong>Lithium<\/strong> \u2014 acetazolamide increases lithium clearance, may reduce therapeutic levels.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 induced hypokalemia may amplify digoxin toxicity.<\/li>\n<li><strong>Metformin<\/strong> \u2014 increased risk of lactic acidosis (theoretical, clinically rare).<\/li>\n<li><strong>Oral contraceptives<\/strong> \u2014 no significant interaction, safe.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Why &#8220;drugs like candy&#8221; is a bad idea<\/h2>\n\n\n\n<p>I am not a big fan of &#8220;just-in-case&#8221; pharmacological prophylaxis. In the climbing community there is a tendency to take acetazolamide &#8220;for safety&#8221; before every expedition above 3000 m \u2014 regardless of ascent pace, predispositions, or medical history. In my opinion this is an error for several reasons:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Natural acclimatization<\/strong> is a physiological process with more durable effects (on subsequent expeditions the body &#8220;remembers&#8221; parts of the mechanism).<\/li>\n<li><strong>Side effects are real<\/strong> \u2014 paresthesias, diuresis-related insomnia, taste changes are not a comfort worth paying for in a healthy person with time to acclimatize.<\/li>\n<li><strong>False sense of security<\/strong> \u2014 some climbers ignore AMS symptoms &#8220;because they&#8217;re on Diamox&#8221;. The drug reduces risk but does not eliminate it.<\/li>\n<li><strong>Cost and logistics<\/strong> \u2014 prescription drug, requires consultation, unnecessarily complicates preparation for those without indications.<\/li>\n<\/ul>\n\n\n\n<p>Acetazolamide prophylaxis makes sense in people with <strong>HAPE\/HACE history<\/strong>, <strong>logistics-forced rapid ascent<\/strong> (e.g. flying to Cusco at 3700 m), or <strong>inability to maintain the 300\u2013500 m rule<\/strong>. For the rest \u2014 gradual ascent, hydration, rest day after each 1000 m, and symptom monitoring.<\/p>\n\n\n\n<p>Specific prophylactic and therapeutic dosing in a dedicated article: <a href=\"\/en\/diamox-acetazolamide-dosing\/\">Diamox (acetazolamide) \u2014 prophylactic and therapeutic dosing<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently asked questions<\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"faq-q-acm-en-1\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Does acetazolamide accelerate acclimatization or just mask symptoms?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>It accelerates \u2014 this is not a symptomatic agent. The mechanism (metabolic acidosis \u2192 respiratory center stimulation \u2192 hyperventilation \u2192 higher saturation) pharmacologically forces a response the body makes spontaneously, just too slowly. RCT meta-analyses show real reduction in AMS incidence (30\u201350%) \u2014 not a placebo effect.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-q-acm-en-2\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Why 125 mg dose, not 250 mg for prophylaxis?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Studies from the last 20 years show 125 mg twice daily gives the same preventive efficacy as 250 mg twice daily, with lower side effect frequency (paresthesias, diuresis, taste changes). WMS 2019 guidelines recommend 125 mg BID as the prophylactic dose. The 250 mg BID dose remains for established AMS treatment.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-q-acm-en-3\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can acetazolamide be combined with dexamethasone?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Yes, in severe AMS and HACE treatment both drugs are combined \u2014 mechanisms are different and complementary. Dexamethasone reduces intracranial pressure and limits edema; acetazolamide improves ventilation and saturation. HACE dosing: dexamethasone 8 mg single dose + 4 mg every 6 h; acetazolamide 250 mg twice daily. Critical treatment remains descent.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-q-acm-en-4\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can alcohol be consumed while taking acetazolamide?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Not recommended. First, alcoholic beverages (beer, wine) on acetazolamide taste &#8220;strange&#8221; due to disrupted sour taste perception. Second, alcohol worsens diuresis and dehydration risk already increased by the drug itself. Third, alcohol depresses the respiratory center, partly counteracting the therapeutic effect. Above 3000 m I advise against alcohol regardless of medication.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-q-acm-en-5\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Is acetazolamide safe for children?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Yes, but dose must match body mass: 2.5 mg\/kg twice daily (max 125 mg per dose). Children &lt;6 years require individual pediatric expedition medicine assessment. Most medical organizations advise against expeditions above 3500 m in children &lt;10\u201312 years regardless of pharmacotherapy \u2014 children have higher HAPE risk than adults.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\">References<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Luks AM, Auerbach PS, Freer L, et al. <em>Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update<\/em>. Wilderness Environ Med. 2019;30(4S):S3\u2013S18.<\/li>\n<li>Leaf DE, Goldfarb DS. <em>Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness<\/em>. J Appl Physiol. 2007;102(4):1313\u20131322.<\/li>\n<li>Basnyat B, Gertsch JH, Johnson EW, et al. <em>Efficacy of low-dose acetazolamide (125 mg BID) for prophylaxis of acute mountain sickness: RCT<\/em>. High Alt Med Biol. 2003;4(1):45\u201352.<\/li>\n<li>Ward, Milledge &amp; West&#8217;s High Altitude Medicine and Physiology, 6th ed. CRC Press, 2021.<\/li>\n<\/ul>\n\n\n\n<p><em><strong>Medical notice:<\/strong> Acetazolamide (Diuramid\/Diamox) is a prescription drug. Do not use without consulting an expedition or travel medicine physician. This article is educational and does not replace individual health assessment. On expeditions, in emergencies call 112, TOPR 601 100 300, GOPR 985 (Poland) or your local rescue service.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>How exactly does acetazolamide (Diamox\/Diuramid) work? Carbonic anhydrase inhibition, metabolic acidosis, pharmacokinetics, side effects and interactions \u2014 a mountain medicine primer.<\/p>\n","protected":false},"author":2,"featured_media":801,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1110","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aktualnosci"],"_links":{"self":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/comments?post=1110"}],"version-history":[{"count":2,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1110\/revisions"}],"predecessor-version":[{"id":1127,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/posts\/1110\/revisions\/1127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/media\/801"}],"wp:attachment":[{"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/media?parent=1110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/categories?post=1110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medycyna-gorska.pl\/en\/wp-json\/wp\/v2\/tags?post=1110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}